Post date April 28, 2023 Experience MedSci Healthcare Holdings HK$608 million IPO We advised MedSci on its IPO and HKEX listing
Post date April 28, 2023 Experience ZJLD Group HK$5.3 billion IPO We advised ZJLD on its IPO and HKEX listing
Post date April 14, 2023 Experience Beisen Holding HK$155 million IPO We advised Beisen on its IPO and HKEX listing
Post date September 22, 2022 Experience InnoCare Pharma RMB2.9 billion Shanghai IPO This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Post date September 19, 2022 Experience Interra Acquisition HK$1 billion IPO We advised the SPAC on its IPO and HKEX listing
Post date September 1, 2022 Experience Biocytogen HK$549 million IPO We advised Biocytogen on its IPO and HKEX listing
Post date July 12, 2022 Experience Tuya global offering and dual primary listing on the Hong Kong Stock Exchange We advised Tuya Inc. on its HK$141 million global offering and dual primary listing on the HKEX
Post date April 25, 2022 Experience CNOOC RMB28 billion Shanghai IPO This is the largest A-share listing by an energy company in the last 15 years
Post date December 10, 2021 Experience CANbridge Pharmaceuticals HK$685 million IPO We advised CANbridge Pharmaceuticals on its IPO and HKEX listing